Comparison of Hepatic Directed Vesicle (HDV)-Insulin Lispro Versus Insulin Lispro to Further Improve Glycemic Control

Completed · Phase 2

Conditions studied: Diabetes Mellitus, Type 1

In brief

Multi-Center, double blind, active comparator controlled multiple dose safety, tolerability and efficacy study

Key facts

Study ID

NCT03096392

Run by

Diasome Pharmaceuticals

People needed

46

Starts

2017-04-18

Expected to finish

2018-03-18

Last updated by the study team

2018-07-31

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female of age 18 to 65 years, inclusive. Females of child-bearing potential must use a standard and effective means of birth control for the duration of the study
• T1DM ≥12 months
• C-peptide <0.6 ng/mL (single retest allowed)
• Treatment with rapid analog insulin for the previous 6 months and willing to use insulin vial and syringe to deliver rapid acting insulin during the study
• Currently using either insulin glargine (U100 only) or insulin degludec for basal insulin therapy for at least 4 weeks prior to study
• Not using insulin pump delivery systems during the previous 3 months
• Familiarity with continuous glucose monitoring (CGM) technology; subjects need to be not currently using CGM; subjects will NOT use unblinded CGM during the treatment period of the trial
• Willingness to use insulin lispro as the analog bolus insulin during the study period
• BMI ≥18.0 kg/m2 and ≤35.0 kg/m2
• 6.9%≤A1C≤7.9% (single retest allowed)

You may not qualify if…

• Known or suspected allergy to any component of any of the study drugs in this trial.
• A patient who has unstable proliferative retinopathy or maculopathy, and/or severe neuropathy, in particular autonomic neuropathy, as judged by the Investigator
• As judged by the investigator, clinically significant active disease of the gastrointestinal, cardiovascular (including a history of arrhythmia or conduction delays on ECG), hepatic, neurological, renal, genitourinary, or hematological systems, or uncontrolled hypertension (diastolic blood pressure ≥ 100 mmHg and/or systolic blood pressure ≥ 160 mmHg after 5 minutes in the supine position).
• History of any illness or disease that in the opinion of the Investigator might confound the results of the trial or pose additional risk in administering the study drugs to the patient.
• As judged by the Investigator, clinically significant findings in routine laboratory data
• Use of drugs that may interfere with the interpretation of trial results or are known to cause clinically relevant interference with insulin action, glucose utilization, or recovery from hypoglycemia
• Use of oral anti-diabetic or non-insulin anti-diabetic injection therapies (e.g. SGLT-2 inhibitors, pramlintide, GLP-1 agonists, etc.) during the 4 weeks prior to randomization
• Current smokers; if a former smoker, no tobacco products (inhaled, oral or buccal) for the previous 3 months
• Use of e-cigarettes or other nicotine-containing products for the previous 3 months
• Current addiction to alcohol or substances of abuse as determined by the Investigator.
• Pregnancy, breast-feeding, the intention of becoming pregnant, or not using adequate contraceptive measures (adequate contraceptive measures consist of sterilization, intra-uterine device [IUD], oral or injectable contraceptives, barrier methods or abstinence as per investigator discretion).
• Mental incapacity, unwillingness, or language barriers precluding adequate understanding or cooperation in this study
• Symptomatic gastroparesis.
• Receipt of any investigational drug within 4 weeks of Visit 2 in this study
• Any condition (intrinsic or extrinsic) that in the judgment of the Investigator will interfere with trial participation or evaluation of data

Where it is running

• Barbara Davis Center for Diabetes, University of Colorado — Aurora, Colorado, United States
• Baptist Diabetes Associates — Miami, Florida, United States
• Lucas Research, Inc. — Morehead City, North Carolina, United States
• Texas Diabetes and Endocrinology — Austin, Texas, United States
• Texas Diabetes and Endocrinology — Austin, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.